位置:首页 > 产品库 > PSI-7409
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PSI-7409
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PSI-7409图片
CAS NO:1015073-42-3

PSI-7409是 Sofosbuvir (PSI-7977) 的5'-三磷酸活性代谢物。Sofosbuvir (PSI-7977) 是选择性和高活性的 HCV 核苷酸类似物抑制剂。
Cas No.1015073-42-3
Canonical SMILESO[C@@H]([C@@](C)(F)[C@H](N1C(NC(C=C1)=O)=O)O2)[C@H]2COP(O)(OP(OP(O)(O)=O)(O)=O)=O
分子式C10H16FN2O14P3
分子量500.16
溶解度Water: 50 mg/mL (99.97 mM); DMF:< 1 mg/mL (insoluble); DMSO:< 1 mg/mL (insoluble or slightly soluble)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of HCV.

PSI-7409 inhibits the enzymatic activities of these NS5Bδ21 polymerases in a dose-dependent manner. The IC50s for PSI-7409 against GT 1b, 2a, 3a, and 4a NS5B polymerases are 1.6 μM, 2.8 μM, 0.7 μM, and 2.6 μM, respectively. PSI-7409 is a weak inhibitor of DNA Pol α (IC50=550 μM). DNA Pol β and γ are not inhibited by 1 mM PSI-7409. A significant amount of RNA product is made in the presence of 500 μM PSI-7409, about 85%[1]. In clone A cells, the levels of PSI-7409 gradually increases to a maximum concentration of about 25 μm over a period of 48 h. PSI-7409 forms at a much faster rate in primary human hepatocytes, achieving a maximum intracellular concentration of ∼100 μM at 4 h and remains at that concentration for 48 h[2].

[1]. Lam AM, et al. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010 Aug;54(8):3187-96. [2]. Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024